Clonal diversity in KRAS mutant colorectal adenocarcinoma under treatment: Monitoring of cfDNA using reverse hybridization and DNA sequencing platforms.

Bádon, Emese Sarolta; Mokánszki, Attila; Mónus, Anikó; András, Csilla; Méhes, Gábor

Bádon, Emese Sarolta; Mokánszki, Attila; Mónus, Anikó; András, Csilla; Méhes, Gábor.

Afiliação

Bádon ES; Department of Pathology, Faculty of Medicine, University of Debrecen, H-4032, Debrecen, Hungary.
Mokánszki A; Department of Pathology, Faculty of Medicine, University of Debrecen, H-4032, Debrecen, Hungary.
Mónus A; Department of Pathology, Faculty of Medicine, University of Debrecen, H-4032, Debrecen, Hungary.
András C; Department of Oncology, Faculty of Medicine, University of Debrecen, H-4032, Debrecen, Hungary.
Méhes G; Department of Pathology, Faculty of Medicine, University of Debrecen, H-4032, Debrecen, Hungary. Electronic address: gabor.mehes@med.unideb.hu.

Mol Cell Probes ; 67: 101891, 2023 02.

Article em En | MEDLINE | ID: mdl-36586518

Assuntos

Adenocarcinoma; Ácidos Nucleicos Livres; Neoplasias do Colo; Neoplasias Colorretais; Humanos; Proteínas Proto-Oncogênicas p21(ras)/genética; Estudos Prospectivos; Bevacizumab/genética; Bevacizumab/uso terapêutico; Neoplasias Colorretais/genética; Análise de Sequência de DNA; Mutação; Sequenciamento de Nucleotídeos em Larga Escala/métodos

Palavras-chave

Bevacizumab; Cell-free DNA; KRAS mutant; Liquid biopsy; Metastatic colorectal cancer; Next-generation sequencing (NGS); Stripassay

Texto completo

Imprimir

XML

PubMed Links

Buscar no Google

Texto completo: 1 Base de dados: MEDLINE Assunto principal: Neoplasias Colorretais / Adenocarcinoma / Neoplasias do Colo / Ácidos Nucleicos Livres Tipo de estudo: Observational_studies / Prognostic_studies Limite: Humans Idioma: En Ano de publicação: 2023 Tipo de documento: Article

Texto completo

Imprimir

XML

PubMed Links

Buscar no Google